PhagoMed is an Austrian biotech company that develops phage-based drugs to treat persistent bacterial infections. It’s lead program PM-477 is a phage-based lysin active against bacteria of the genus Gardnerella, the lead pathogen in Bacterial Vaginosis. It is being developed as a treatment for patients with recurrent and refractory Bacterial Vaginosis, an area of very high medical need where antibiotics do not work.

PhagoMed is based at the Vienna Biocenter in Vienna, Austria and has a team of fifteen highly skilled people including 8 PhDs. To date it raised >6.5 million euros in private investments and public grants.